gptkbp:instanceOf
|
gptkb:biotechnology
|
gptkbp:acquiredBy
|
gptkb:Cephalon
gptkb:Actavis_Generics
gptkb:Barr_Pharmaceuticals
|
gptkbp:annualReport
|
https://www.tevapharm.com/investors/reports/
|
gptkbp:businessModel
|
multinational
|
gptkbp:CEO
|
gptkb:Richard_Francis
|
gptkbp:chairman
|
gptkb:Amir_Elstein
|
gptkbp:country
|
gptkb:Israel
|
gptkbp:founded
|
gptkb:Salomon,_Levin,_and_Elstein_Ltd.
1901
|
gptkbp:founder
|
gptkb:Yitschak_Levin
gptkb:Chaim_Salomon
gptkb:Moshe_Levin
|
gptkbp:headquarters_location
|
gptkb:Petah_Tikva
|
https://www.w3.org/2000/01/rdf-schema#label
|
Teva Pharmaceuticals
|
gptkbp:industry
|
pharmaceuticals
|
gptkbp:ISIN
|
US8816242098
|
gptkbp:legalForm
|
gptkb:public_company
|
gptkbp:listedOn
|
gptkb:TA-125_Index
gptkb:TA-35_Index
gptkb:Forbes_Global_2000
gptkb:S&P_500_Index
|
gptkbp:logo
|
Teva Pharmaceuticals logo.svg
|
gptkbp:market
|
world's largest generic drug manufacturer
|
gptkbp:member
|
gptkb:Pharmaceutical_Research_and_Manufacturers_of_America
|
gptkbp:mergedInto
|
gptkb:Assia
gptkb:Zori
|
gptkbp:netIncome
|
$-2.35 billion (2022)
|
gptkbp:notable_executive
|
gptkb:Eli_Hurvitz_(former_CEO)
Erez Vigodman (former CEO)
Kåre Schultz (former CEO)
Shlomo Yanai (former CEO)
|
gptkbp:notable_legal_issue
|
gptkb:opioid_litigation_in_the_United_States
price-fixing allegations
|
gptkbp:notableProduct
|
gptkb:Ajovy
gptkb:Austedo
gptkb:Copaxone
|
gptkbp:numberOfEmployees
|
~37,000
|
gptkbp:parentCompany
|
gptkb:Teva_Pharmaceutical_Industries_Ltd.
|
gptkbp:products
|
generic drugs
over-the-counter drugs
specialty medicines
|
gptkbp:revenue
|
$15.8 billion (2022)
|
gptkbp:servesArea
|
worldwide
|
gptkbp:stockExchange
|
gptkb:New_York_Stock_Exchange
gptkb:Tel_Aviv_Stock_Exchange
|
gptkbp:stockSymbol
|
gptkb:TEVA
|
gptkbp:subsidiary
|
gptkb:Teva_USA
gptkb:Teva_Canada_Limited
gptkb:Teva_UK_Limited
|
gptkbp:website
|
https://www.tevapharm.com/
|
gptkbp:bfsParent
|
gptkb:Adderall
gptkb:The_Pill
gptkb:Chemi_Peres
gptkb:Ajovy
gptkb:Austedo
gptkb:Copaxone
|
gptkbp:bfsLayer
|
6
|